The Permanent Vice Minister of Health has officially signed into effect a comprehensive Circular outlining strict regulatory requirements for implementing free medication support programs at medical examination and treatment facilities. Rooted in the statutory framework of the national Law on Drugs, the updated administrative decree establishes a closed-loop monitoring matrix engineered to ensure that supportive pharmaceutical assets are distributed to patients with maximum equity, transparency, and clinical efficiency. Crucially, the mandate permanently bans commercial enterprises from exploiting these welfare initiatives for promotional marketing or illicit market positioning. This regulation excludes medications classified under non-refundable grants that are already accounted for within state budget revenues.
The operational baseline, technical compliance criteria, and multi-lateral institutional responsibilities outlined in the Circular include:
-
Patient Stratification and Financial Architecture: Eligible recipients must be definitively diagnosed, receive a validated prescription matching the program’s specific clinical indications, and formally participate on a voluntary basis. For patients covered under national health insurance profiles, the Social Insurance Fund is legally prohibited from reimbursing any pharmaceutical volumes already supplied free of charge through the support mechanism.
-
Clinical and Regulatory Alignment: All medications deployed within these support channels must hold valid marketing authorizations in Vietnam. Clinical indicators and prescribing workflows must strictly correspond to at least one of the following official reference materials: diagnostic and treatment guidelines promulgated by the Ministry of Health (or internal hospital guidelines compiled by the Drug and Treatment Committee if federal guidelines remain pending), authorized product labels, or the latest edition of the National Formulary. Furthermore, the participating healthcare facility must possess a licensed scope of medical practice that accommodates the drug’s specialized indications.
-
Dedicated Logistics and Storage Protocols: Supportive pharmaceuticals must be safely stored in dedicated inventory zones featuring prominent, independent labels for ready identification. Attending physicians are required to explicitly document within patient medical records or physical prescriptions that the specific drug volume is sourced from the free support program. In the case of destroying expired, broken, or degraded medications, the financial liability and operational execution responsibilities must be explicitly defined within the bilateral contract executed between the hospital network and the pharmaceutical distributor.
-
Mandatory Obligations for Healthcare Facilities: Hospitals are required to transparently publish all program details across institutional web portals or public notice areas. Facilities must establish precise internal workflows to prevent resource waste or clinical abuse. Medical staff are mandated to provide exhaustive consultations covering treatment regimens, clinical efficacy, adverse reactions, relative cost-benefit comparisons with alternative therapies, and patient rights. Additionally, dispensing schedules must be planned against actual patient volumes to guarantee transparent distribution.
-
Compliance and Prohibitions for Pharmaceutical Enterprises: Drug suppliers and commercial distributors are legally responsible for maintaining the lawful origin, supply-chain continuity, and structural quality of all contracted medications. The Ministry of Health strictly prohibits businesses from utilizing free drug programs as commercial tools for advertising, corporate marketing, or product promotions targeted at healthcare networks or consumers. It further bans the exploitation of these philanthropic programs to forge anti-competitive advantages in the wider pharmaceutical market.